Meeting Banner
Abstract #4379

Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a Multicenter Intra-individual Crossover Comparison of Gadobutrol with Gadoteridol (The TRUTH study)

Martin P Smith 1 , Kenneth R Maravilla 2 , Stefano Bastianello 3 , Eva Bueltmann 4 , Toshinori Hirai 5 , Tiziano Frattini 6 , Cesare Colosimo 7 , and Gianpaolo Pirovano 8

1 Department of Radiology, Beth Israel Deaconess Medical Center, Boston, MA, United States, 2 University of Washington, WA, United States, 3 Neuroradiology Department, University of Pavia, Pavia, Italy, 4 Oberartzin Institut fur Diagnostiche und Interventionelle Neuroradiologie, Hannover, Germany, 5 Kumamoto University, Kumamoto, Japan, 6 Ospedale Valduce, Como, Italy, 7 Policlinico Agostino Gemelli, Rome, Italy, 8 Bracco Diagnostics Inc., Monroe, NJ, United States

Two-hundred-twenty nine patients with suspected brain tumors underwent two identical, randomized MRI exams at 1.5T; one enhanced with 0.1 mmol/kg gadoteridol (ProHance) and the other with 0.1 mmol/kg gadobutrol (Gadavist). Three blinded readers evaluated matched image sets for qualitative (lesion extent, delineation, morphology, enhancement, global preference) and quantitative (LBR, % enhancement) lesion enhancement and randomized, unmatched image sets for accuracy in lesion diagnosis vs. final clinical diagnosis. No significant differences were noted by any reader for any end-point. The results confirm that the higher concentration of the Gadavist formulation has no impact on routine morphologic imaging of brain tumors.

This abstract and the presentation materials are available to members only; a login is required.

Join Here